LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of WPP plc ("WPP†or the "Company†) (NYSE: WPP) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON WPP PLC (WPP), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 9, 2025, WPP provided an update for the first half of 2025, disclosing to investors that. ...

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of TrueCar, Inc. to Fair Holdings, Inc. at a price of $2.55 per share for TrueCar shareholders [1]. Group 1: Investigation Details - The investigation focuses on whether TrueCar and its board of directors violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders [3]. - Concerns include whether Fair Holdings is underpaying for TrueCar and if all material information necessary for shareholders to assess the merger consideration has been disclosed [3]. Group 2: Potential Actions - On behalf of TrueCar shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, and other relief related to the proposed transaction [4].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement of the trial results [3]. Legal Implications - Investors in MoonLake are encouraged to seek additional information regarding potential legal options due to the investigation and the significant stock price decline [1][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation, with a strong track record of recovering substantial amounts for clients [6].

Core Insights - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, a treatment for inflammatory diseases [1][2][3] Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2] Recent Developments - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3] - Following the announcement, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3] Legal Context - Bleichmar Fonti & Auld LLP is investigating the situation and encourages investors to seek additional information regarding potential legal options [1][4]

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement [3]. Legal Implications - Investors in MoonLake are encouraged to seek additional information regarding potential legal options due to the investigation [1][4]. - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing affected shareholders on a contingency fee basis [6].

RADNOR, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Firefly Aerospace Inc. (NASDAQ: FLY) (“Firefly Aerospace”). On September 22, 2025, Firefly Aerospace reported its financial results for the second quarter of fiscal year 2025 – Firefly Aerospace’s initial quarterly results as a public company since its initial public offering the prior month. ...

On September 22, 2025, Firefly Aerospace reported its financial results for the second quarter of fiscal year 2025 – Firefly Aerospace's initial quarterly results as a public company since its initial public offering the prior month. Specifically, Firefly Aerospace reported revenue of $15.5 million, a year-over-year decline of more than 27%, while reporting total operating expenses of $58.3 million, a year-over-year increase of more than 12%. On this news, the price of Firefly Aerospace's stock declined by ...

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between Axcelis Technologies, Inc. and Veeco Instruments Inc. for Axcelis shareholders, who are expected to own approximately 58% of the combined company upon closing [1]. Group 1: Investigation Details - The investigation focuses on whether Axcelis and its board violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [3]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [4]. Group 2: Legal Rights and Options - Axcelis shareholders are encouraged to learn more about their legal rights and options regarding the merger [2].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of First Savings Financial Group, Inc. to First Merchants Corporation, specifically whether the exchange ratio of 0.85 shares of First Merchants common stock per share of First Savings common stock is equitable for shareholders [1][3]. Group 1 - The investigation focuses on potential violations of federal securities laws and breaches of fiduciary duties by First Savings and its board of directors [3]. - Key concerns include whether the best possible consideration was obtained for shareholders, if First Merchants is underpaying for First Savings, and whether all material information necessary for shareholders to assess the merger was disclosed [3][4]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief [4].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal. ...